Overview

Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes

Status:
Terminated
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
Assess the safety and toleration of CP-464,005 and Inhaler following 1-year (52 week) administration to Type 1 and Type 2 diabetes patients (non-smokers)
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Treatments:
Insulin
Insulin, Globin Zinc